ArticleOncotarget2017
Acceleration of leukocytes' epigenetic age as an early tumor and sex-specific marker of breast and colorectal cancer.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Epigenetic Ageing and Breast Cancer Risk: A Systematic Review.Cancer medicine · 2024Pooled it
- Methylation-based markers of aging and lifestyle-related factors and risk of breast cancer: a pooled analysis of four prospective studies.Breast cancer research : BCR · 2022Pooled it
- Pooled it
- Pooled it
- The epigenetic clock as a predictor of disease and mortality risk: a systematic review and meta-analysis.Clinical epigenetics · 2019Pooled it
- Impact of a diet and activity health promotion intervention on regional patterns of DNA methylation.Clinical epigenetics · 2019Trial
- Intake of ultra-processed foods and accelerated epigenetic aging of colorectal tissues.JNCI cancer spectrum · 2026Article
- From the lab to lifestyle: epigenetic clocks in personalized aging and health.Biogerontology · 2026Review
- Association of Epigenetic Aging Biomarkers With Risk of MASLD-Related HCC.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Epigenetic age and accelerated aging phenotypes: a tumor biomarker for predicting colorectal cancer.Aging · 2025Article
- Article
- A State of the Science Review of Human Health Effects of the Michigan Polybrominated Biphenyl Contamination after Five Decades.Environmental health perspectives · 2025Review
- A Sex-Specific Minimal CpG-Based Model for Biological Aging UsingInternational journal of molecular sciences · 2025Article
- Biological Aging in Combination with Lifestyle Factors in the Blood-Based Methylome: A Biomarker for Colorectal Cancer Susceptibility in African American Women.Aging and disease · 2025Article
- Review
- Biological Age Acceleration and Colonic Polyps in Persons under Age 50.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Article
- Targeting the epigenetically older individuals for geroprotective trials: the use of DNA methylation clocks.Biogerontology · 2024Review
- Blood-Based Epigenetic Age Acceleration and Incident Colorectal Cancer Risk: Findings from a Population-Based Case-Control Study.International journal of molecular sciences · 2024Article
- Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice.Cellular reprogramming · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Changes in blood epigenetic age have been associated with several pathological conditions and have recently been described to anticipate cancer development. In this work, we analyze a publicly available leukocytes methylation dataset to evaluate the relation between DNA methylation age and the prospective development of specific types of cancer. We calculated DNA methylation age acceleration using five state-of-the-art estimators (three multi-site: Horvath, Hannum, Weidner; and two CpG specific: ELOV2 and FHL2) in a cohort including 845 subjects from the EPIC-Italy project and we compared 424 samples that remained cancer-free over the approximately ten years of follow-up with 235 and 166 subjects who developed breast and colorectal cancer, respectively. We show that the epigenetic age estimated from blood DNA methylation data is statistically significantly associated to future breast and male colorectal cancer development. These results are corroborated by survival analysis that shows significant association between age acceleration and cancer incidence suggesting that the chance of developing age-related diseases may be predicted by circulating epigenetic markers, with a dependence upon tumor type, sex and age estimator. These are encouraging results towards the non-invasive and perspective usage of epigenetic biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.